SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Arena S, Barbieri F, Thellung S, et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol. 2004; 66: 155-166.
  • 2
    Kaminski JM, Movsas B, King E, et al. Metastatic meningioma to the lung with multiple pleural metastases. Am J Clin Oncol. 2001; 24: 579-582.
  • 3
    Central Brain Tumor Registry of the United States (CBTRUS). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2010.
  • 4
    Goldberg H. Extraaxial brain tumors. In: Atlas SV ed. Magnetic Resonance Imaging of the Brain and Spine. 1st ed. New York: Raven Press; 1991: 327-378.
  • 5
    Nathoo N, Ugokwe K, Chang AS, et al. The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas. J Neurooncol. 2007; 81: 167-174.
  • 6
    Karasick JL, Mullan SF. A survey of metastatic meningiomas. J Neurosurg. 1974; 40: 206-212.
  • 7
    Figueroa BE, Quint DJ, McKeever PE, Chandler WF. Extracranial metastatic meningioma. Br J Radiol. 1999; 72: 513-516.
  • 8
    Baisden BL, Hamper UM, Ali SZ. Metastatic meningioma in fine-needle aspiration (FNA) of the lung: cytomorphologic finding. Diagn Cytopathol. 1999; 20: 291-294.
  • 9
    Reubi JC, Maurer R, Klijn JG, et al. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab. 1986; 63: 433-438.
  • 10
    Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999; 20: 157-198.
  • 11
    Lamberts SWJ, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab. 2002; 13: 451-457.
  • 12
    Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006; 17: 1733-1742.
  • 13
    Klutmann S, Bohuslavizki KH, Brenner W, et al. Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med. 1998; 39: 1913-1917.
  • 14
    Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007; 69: 969-973.
  • 15
    Macdonald D, Cascino T, Schold S Jr, Cairncross J. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 1277-1280.
  • 16
    Pasquier D, Bijmolt S, Veninga T, et al; Rare Cancer Network. Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys. 2008; 71: 1388-1393.
  • 17
    Rockhill J, Mrugala M, Chamberlain MC. Intracranial meningiomas: an overview of diagnosis and treatment. Neurosurg Focus. 2007; 23: E1.
  • 18
    Burger PC, Scheithauer BW. Meningioma 2007: Tumors of the Central Nervous System. Washington, DC: Armed Forces Institute of Pathology; 2007: 331-362.
  • 19
    Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ. Meningiomas. In: Kleihues P, Cavenee WK, eds. 2000 WHO Classification of Tumors. Tumors of the Nervous System. Lyon, France: IARC; 2000: 175-196.
  • 20
    Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol. 1997; 21: 1455-1465.
  • 21
    Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002; 61: 215-225; discussion 226-229.
  • 22
    Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004; 62: 1210-1212.
  • 23
    Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957; 20: 22-39.
  • 24
    Ko K-W, Nam D-H, Kong D-S, Lee J II, Park K, Kim J-H. Relationship between malignant subtypes of meningioma and clinical outcome. J Clin Neurosci. 2007; 14: 747-753.
  • 25
    Ohta M, Iwaki T, Kitamoto T, Takeshita I, Tateishi J, Fukui M. MIB1 staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management. Cancer. 1994; 74: 3176-3189.
  • 26
    Kallio M, Sankila R, Hakulinen T, Jaaskelainen J. Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery. 1992; 31: 2-12.
  • 27
    Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985; 62: 18-24.
  • 28
    Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SW. Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res. 1987; 47: 5758-5764.
  • 29
    Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB. All five cloned human somatostatin receptors (hSSTR1–5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun. 1994; 198: 605-612.
  • 30
    Klutmann S, Bohuslavizki KH, Tietje N, et al. Clinical value of 24-hour delayed imaging in somatostatin receptor scintigraphy for meningioma. J Nucl Med. 1999; 40: 1246-1251.
  • 31
    Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM. Epidemiology of intracranial meningioma. Neurosurgery. 2005; 57: 1088-1095; discussion 1088-1095.
  • 32
    Plachsinka A, Mikolajczak R, Maecke H, et al. Efficacy of 99mTc-EDDA/HYNIC-TOC scintigraphy in differential diagnosis of solitary pulmonary nodules. Cancer Biother Radiopharm. 2004; 19: 613-620.
  • 33
    Wang F, Wang Z, Yao W, Xie H, Xu J, Tian L. Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging. J Nucl Med. 2007; 48: 1442-1448.
  • 34
    Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol. 2005; 23: 3175-3185.
  • 35
    Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer. 1999; 85: 2046-2056.
  • 36
    Enam SA, Abdulrauf S, Mehta B, Malik GM, Mahmood A. Metastasis in meningioma. Acta Neurochir (Wien). 1996; 138: 1172-1177; discussion 1177-1178.